Side-by-side · Research reference

IpamorelinvsMatrixyl

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED21/57 cited

BAnimal-MechanisticHUMAN-REVIEWED9/39 cited

Ipamorelin

Selective GHRP · Ghrelin Mimetic

200–300 mcgPer doseRaun 1998

Phase 1Evidence levelRaun 1998 Sigalos 2018

~2 hrHalf-lifeRaun 1998

SQ · Multiple sites · 1–3×/day

Matrixyl

Cosmeceutical Pentapeptide · Topical Anti-Aging

TopicalRoute

5-AALength (KTTKS)Gomes 2022

Collagen I/IIIPrimary targetPaccola 2025

Topical · Dermal · Twice Daily

01Mechanism of Action

Parameter

Ipamorelin

Matrixyl

Primary target

Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998

Dermal fibroblastsPaccola 2025

Pathway

GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998 Bowers 1991

Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling

Downstream effect

GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002

Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025

Feedback intact?

Yes — pulsatile pattern preserved; somatostatin feedback activeBowers 2002

—

Origin

Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998

Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022

Antibody development

Not reported in short-term studies

—

02Dosage Protocols

Parameter

Ipamorelin

Matrixyl

Standard dose

200–300 mcg per injectionRaun 1998

Anecdotal community range; clinical doses 1–3 mg IV in trials.

—

Frequency

1–3× per day

Once daily pre-sleep is most common; twice or thrice for advanced users.

—

Lower / starter dose

100 mcg per dose

—

Evidence basis

Phase 1 + clinical practiceRaun 1998 Sigalos 2018

—

Duration

8–12 weeks on / 4 weeks off (anecdotal)

GHS-R desensitisation reported with continuous dosing.

8–12 weeks minimum for visible effect

Collagen synthesis requires sustained application.

Reconstitution

Bacteriostatic water; typical 2 mL per 5 mg vial

—

Timing

Pre-sleep + fasted preferred; 30 min away from food

—

Half-life

~2 hoursRaun 1998

Longer than GHRP-6 (15 min); shorter than CJC-1295-DAC (~8 days).

—

Formulation concentration

—

0.5–5% in topical vehicle

Common cosmeceutical range; higher concentrations in clinical formulations.

Application frequency

—

Twice daily (AM/PM)

Standard cosmeceutical protocol.

In vitro evidence

—

Fibroblast viability + ECM gene upregulationPaccola 2025

Vehicle

—

Serum, cream, or emulsion base

Lipophilic carriers enhance penetration.

04Side Effects & Safety

Parameter

Ipamorelin

Matrixyl

Cortisol elevation

Negligible vs other GHRPsRaun 1998

—

Prolactin elevation

NegligibleRaun 1998

—

Hunger

Mild appetite increase via ghrelin-receptor crosstalk

—

Injection site reaction

Mild irritation possible

—

GH excess (overdose)

Joint pain, edema, insulin resistance

—

IGF-1 elevation

Dose-dependent; monitor with chronic high-dose use

—

Cancer risk

Theoretical via GH/IGF-1 axis; contraindicated in active malignancy

—

Pregnancy / OB

Avoid

—

Irritation

—

Mild erythema, pruritus in sensitive skin (rare)

Allergic reaction

—

Contact dermatitis (uncommon)

Systemic absorption

—

Negligible — topical application only

Absolute Contraindications

Ipamorelin

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Matrixyl

·Known hypersensitivity to palmitoyl peptides

Relative Contraindications

Ipamorelin

·Untreated diabetes
·Severe insulin resistance
·Concurrent corticosteroid use (theoretical desensitisation)

Matrixyl

·Active dermatitis or open wounds at application site

05Administration Protocol

Parameter

Ipamorelin

Matrixyl

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.

Wash face with gentle cleanser. Pat dry.

2. Injection site

Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.

Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.

3. Timing

Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.

Twice daily — morning and evening. Apply before heavier creams or sunscreen.

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

Ipamorelin

+ Tesamorelin

Strong

View Tesamorelin →

Ipamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.

Ipamorelin: 200–300 mcg SQ · pre-sleep
Tesamorelin: 2 mg SQ · same injection · pre-sleep
Primary benefit: Maximal GH pulsatility, fat loss, recovery, sleep depth

Raun 1998 Bowers 2002

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

CJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.

Ipamorelin: 200–300 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation matching physiological pattern

Teichman 2006 Ionescu 2006

Matrixyl

+ GHK-Cu

Multi-pathway

View GHK-Cu →

Matrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.

Matrixyl: 0.5–5% topical serum · AM/PM
GHK-Cu: 1–2% topical serum · same application
Frequency: Twice daily
Primary benefit: Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity